Duchenne Muscular Dystrophy Drugs

Duchenne muscular dystrophy (DMD) is a progressive X-linked genetic disorder caused primarily by pathogenic variants affecting dystrophin production. Drug development and clinical management focus on slowing functional decline, preserving mobility, addressing cardiopulmonary complications, and expanding access to mutation-specific or disease-modifying approaches. The treatment landscape combines corticosteroids, exon-skipping therapies for eligible mutations, and supportive interventions across neuromuscular, cardiac, respiratory, orthopedic, and rehabilitative care.

The DMD treatment landscape is moving from predominantly supportive management toward earlier diagnosis, genotype-informed treatment selection, and coordinated multidisciplinary care. Newborn screening research, improved genetic testing, and referral pathways can shorten diagnostic delays and identify patients before substantial muscle loss occurs. At the same time, regulatory attention is increasingly focused on functional outcomes, dystrophin restoration, safety monitoring, and the practical needs of pediatric and transitioning adult patients.

Artificial intelligence can contribute to DMD research and care by analyzing genetic, imaging, electronic health record, and longitudinal functional data. Potential applications include variant interpretation, automated assessment of motor performance, identification of disease trajectories, trial recruitment, and detection of cardiac or respiratory deterioration. Its value depends on representative datasets, clinically validated endpoints, transparent models, privacy safeguards, and integration with specialist judgment; AI should support rather than replace neuromuscular expertise.

North America benefits from established neuromuscular centers, genetic testing infrastructure, and experience with advanced therapies, although affordability and payer criteria remain important barriers. Europe combines strong specialist networks with differing national reimbursement and health-technology-assessment processes across the European Union and neighboring systems. Asia-Pacific includes sophisticated treatment and research capabilities alongside substantial access gaps between urban and rural populations. Latin America continues to face diagnostic delays, limited specialist coverage, and uneven access to genetic services. The Middle East is developing specialized care capacity, while access and continuity differ across countries. Africa faces pronounced constraints in genetic diagnostics, multidisciplinary services, and availability of long-term supportive care.

ASEAN countries show varied diagnostic and reimbursement capacity, making regional referral networks and shared clinical protocols particularly relevant. BRICS members encompass major research and manufacturing capabilities but also wide differences in public-health coverage and access. The European Union can support cross-border standards, registries, and coordinated evidence generation despite national reimbursement variation. G7 members generally possess advanced regulatory, research, and specialist-care infrastructures, while continuing to address affordability and transition to adult care. GCC countries have opportunities to expand centralized genetic and neuromuscular services through coordinated health systems. NATO members span diverse health systems, but collaboration in preparedness, data standards, and specialist training can strengthen continuity of care.

Australia is positioned to strengthen coordinated rare-disease services across geographically dispersed populations. Brazil and Mexico face priorities in earlier diagnosis, public-system access, and specialist distribution. Canada must address regional disparities and sustainable coverage across provinces and territories. China and India have substantial opportunities to expand genetic testing, registries, and multidisciplinary pediatric neuromuscular care. Japan and South Korea combine advanced clinical capabilities with continuing needs in long-term access and transition services. France, Germany, Italy, and Spain have established expertise but must navigate evidence requirements, reimbursement variation, and continuity across life stages. The United Kingdom can build on specialist networks while addressing access consistency and long-term service coordination. Russia faces challenges related to diagnostic reach, treatment availability, and continuity across regions. The United States has extensive specialist and research capacity, with persistent concerns involving insurance coverage, treatment eligibility, affordability, and equitable access.

Leaders should prioritize therapies and care models that demonstrate meaningful, durable benefits across mobility, respiratory function, cardiac health, quality of life, and caregiver burden. Development programs should incorporate genetically and geographically diverse populations, patient-centered endpoints, transparent evidence plans, and post-treatment safety monitoring. Partnerships with diagnostic laboratories, specialist centers, patient organizations, and public payers can improve identification and continuity of care. Companies and health systems should also invest in clinician education, decentralized support, interoperable registries, and responsible AI tools, while designing access programs that address affordability, rural delivery, and transition from pediatric to adult services.

This executive summary uses a structured qualitative synthesis of established DMD disease biology, treatment modalities, care pathways, diagnostic practices, regulatory considerations, and health-system access factors. Regional, group, and country observations are framed around documented differences in specialist capacity, genetic-testing infrastructure, reimbursement, research activity, and multidisciplinary care. The analysis avoids market estimates and company-specific claims, and it treats artificial intelligence as an enabling technology whose clinical usefulness requires validation, governance, and appropriate data quality.

DMD care is entering a more targeted and data-enabled phase, but therapeutic progress will translate into better outcomes only when diagnosis, treatment selection, monitoring, rehabilitation, and supportive services function as one coordinated pathway. The central priorities are earlier identification, robust evidence, equitable access, and sustained multidisciplinary care. Regional partnerships, stronger registries, responsible use of AI, and patient-centered outcome measurement can help convert scientific advances into durable benefits for individuals and families living with DMD.